Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225804 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT06225804: Recruiting Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Abbisko Therapeutics Co.
NCT06225804 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 164 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06225804, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
Primary Outcome
Dose-limiting toxicities
Conditions Studied
Interventions
- DRUG ABSK112
Study Locations (14)
California
- Precision NextGen Oncology - Beverly Hills
Anhui
- Anhui Chest Hospital - Hefei
Fujian
- Fujian Cancer Hospital - Fuzhou
Harbin
- The first Affiliated Hospital of Xi'an Jiaotong University - Xi'an
Heilongjiang
- Harbin Medical University Cancer Hospital - Harbin
Henan
- Henan Cancer Hospital - Zhengzhou
Hubei
- Union Hospital Tongji Medical College Huzhong University of Science and Techology - Wuhan
Hunan
- Hunan Cancer Hospital - Changsha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What NCT06225804 shows while recruiting
NCT06225804 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABSK112 is the first listed.
NCT06225804 lists 14 locations in 14 states (California, Anhui, Fujian).
Frequently Asked Questions
What is clinical trial NCT06225804 about?
NCT06225804 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer". This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
What is the current status of trial NCT06225804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2024-02-22. Estimated completion is 2028-03.
What conditions does trial NCT06225804 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06225804?
The interventions under investigation include: ABSK112 (DRUG).
Who is sponsoring clinical trial NCT06225804?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225804 being conducted?
This trial has 14 study locations across California, Anhui, Fujian, Harbin, Heilongjiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06225804's enrollment target sits among peer trials
164 188th of 454 higher than 267 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI